AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9706795 — intervention group
Group type: EXPERIMENTAL
Intervention: RHL (rose-hip drink with fermented oats containing Lactobacillus plantarum DSM 9843)
Number of subjects: 48
Study 9706795 — intervention group
Group type: EXPERIMENTAL
Intervention: RHL
Number of subjects: 48
Study 9706795 — intervention group
Group type: COMPARATOR
Intervention: RH (pure rose-hip drink)
Number of subjects: 48
Study 9706795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 9706795 — intervention group
Group type: COMPARATOR
Intervention: RH
Number of subjects: 48
Study 7678047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 43
Study 7678047 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 43
Study 3524419 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and ticarcillin for 27 to 62 days (mean, 42 days)
Number of subjects: 18
Study 3524419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 4 g per day for 26 to 63 days (mean, 45 days)
Number of subjects: 18
Study 3524419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 18
Study 29560635 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 62
Study 29560635 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Mobilization (NM)
Number of subjects: 62
Study 29560635 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with Neural Mobilization (EA+NM)
Number of subjects: 62
Study 26902950 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 1016
Study 26902950 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 1016
Study 24521106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy
Number of subjects: 2001
Study 24521106 — intervention group
Group type: COMPARATOR
Intervention: Nodal observation
Number of subjects: 2001
Study 22381051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 48
Study 22381051 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil anesthesia
Number of subjects: 48
Study 20116803 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced cardiac magnetic resonance (ceCMR)
Number of subjects: 34
Study 20116803 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiographic QRS scoring
Number of subjects: 34
Study 18052520 — intervention group
Group type: EXPERIMENTAL
Intervention: learner‐centered hand washing program
Number of subjects: 0
Study 16229991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin (400 mg once a day)
Number of subjects: 367
Study 16229991 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piperacillin-tazobactam (3.0/0.375 g every 6 h) followed by oral amoxicillin-clavulanate (800 mg every 12 h)
Number of subjects: 367
Study 16229991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intravenous/oral moxifloxacin
Number of subjects: 367
Study 16229991 — intervention group
Group type: COMPARATOR
Intervention: Intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate
Number of subjects: 367
Study 12095814 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 20
Study 12095814 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical pachymetry (OP)
Number of subjects: 20
Study 12095814 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral eye without contact lens)
Number of subjects: 20
Study 12095814 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 20
Study 12095814 — intervention group
Group type: EXPERIMENTAL
Intervention: OP
Number of subjects: 20
Study 10447907 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Quincke needle
Number of subjects: 57
Study 10447907 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge Whitacre needle
Number of subjects: 57
Study 8522666 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinastatin (100,000 U dose immediately after arrival, followed by three 100,000 U doses at 8-hour intervals within the first 24 hours)
Number of subjects: 40
Study 8522666 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation (CPR) procedures
Number of subjects: 40
Study 8522666 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinastatin
Number of subjects: 40
Study 8522666 — intervention group
Group type: COMPARATOR
Intervention: Control (standard CPR)
Number of subjects: 40
Study 2034708 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation in conjunction with voluntary isometric exercise
Number of subjects: 30
Study 2034708 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback in conjunction with voluntary isometric exercise
Number of subjects: 30
Study 2034708 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 30
Study 2034708 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 30
Study 6794083 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 21
Study 6794083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 21
Study 31866328 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin Inhale (400 mg, aerosolised, administered every 12 h for 10 days)
Number of subjects: 725
Study 31866328 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, aerosolised, administered every 12 h for 10 days)
Number of subjects: 725
Study 31866328 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin Inhale
Number of subjects: 725
Study 31866328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 29671202 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.01-0.32 mg/kg in healthy adults; 0.02-0.12 mg/kg in adults with GHD; 0.02-0.16 mg/kg in children with GHD)
Number of subjects: 0
Study 27694343 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain amyloid load (measured by florbetapir F18 positron emission tomography)
Number of subjects: 269
Study 27694343 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-repetition chair rise performance (maximum speed)
Number of subjects: 269
Study 26359749 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated intervention (iBASIS-VIPP)
Number of subjects: 54
Study 22706336 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily (1 drop PM)
Number of subjects: 142
Study 22706336 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (1 drop AM and PM)
Number of subjects: 142
Study 22706336 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Latanoprost vs Timolol
Number of subjects: 142
Study 21193924 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoupled crank system
Number of subjects: 18
Study 21193924 — intervention group
Group type: COMPARATOR
Intervention: Traditional crank system
Number of subjects: 18
Study 19550390 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 24
Study 19550390 — intervention group
Group type: COMPARATOR
Intervention: Standard care (including dietary restriction programme)
Number of subjects: 24
Study 17760930 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 210
Study 17760930 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 210
Study 15476485 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and Mycophenolate Mofetil (MMF) with a 7-day course of prednisolone
Number of subjects: 101
Study 15476485 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (anti-CD25 mAb) administered to high immunological risk patients
Number of subjects: 101
Study 11544563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic pregnancies
Number of subjects: 76
Study 11544563 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetes pregnancies
Number of subjects: 76
Study 11544563 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus pregnancies
Number of subjects: 76
Study 11544563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic pregnancies complicated by gestational hypertension
Number of subjects: 76
Study 11544563 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated pregnancies
Number of subjects: 76
Study 9766411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide 1 mg/kg
Number of subjects: 13
Study 9766411 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide 2 mg/kg
Number of subjects: 13
Study 9766411 — intervention group
Group type: COMPARATOR
Intervention: Control (no nebulization)
Number of subjects: 13
Study 8877293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.33 or 3.3 micrograms.min‐1.dl‐1)
Number of subjects: 36
Study 8877293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (2.5 micrograms.min‐1.dl‐1)
Number of subjects: 36
Study 8877293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8877293 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 36
Study 2565995 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms SOM 1397 CL
Number of subjects: 10
Study 2565995 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms SOM 1397 CL
Number of subjects: 10
Study 2565995 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms SOM 1397 CL
Number of subjects: 10
Study 2565995 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram SOM 1397 CL
Number of subjects: 10
Study 337094 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenicillin, cephalothin, and gentamicin (CCG)
Number of subjects: 51
Study 337094 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue antibiotics (CCG + chloramphenicol or clindamycin)
Number of subjects: 51
Study 337094 — intervention group
Group type: COMPARATOR
Intervention: Stop antibiotics
Number of subjects: 51
Study 337094 — intervention group
Group type: EXPERIMENTAL
Intervention: CCG
Number of subjects: 51
Study 31836199 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VMP (daratumumab, bortezomib, melphalan, and prednisone)
Number of subjects: 706
Study 31836199 — intervention group
Group type: COMPARATOR
Intervention: VMP (bortezomib, melphalan, and prednisone)
Number of subjects: 706
Study 30300017 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV_G)
Number of subjects: 42
Study 30300017 — intervention group
Group type: COMPARATOR
Intervention: Control (C_G)
Number of subjects: 42
Study 26324740 — intervention group
Group type: EXPERIMENTAL
Intervention: lenvatinib 24 mg orally per day (n = 261)
Number of subjects: 392
Study 26324740 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 131)
Number of subjects: 392
Study 26324740 — intervention group
Group type: EXPERIMENTAL
Intervention: lenvatinib 24 mg orally per day
Number of subjects: 392
Study 23921307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d)
Number of subjects: 72
Study 23921307 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg/d)
Number of subjects: 72
Study 21860340 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) sublingual tablet (14-20 mg)
Number of subjects: 3
Study 19626663 — intervention group
Group type: COMPARATOR
Intervention: INGAP peptide 600 mg/day
Number of subjects: 189
Study 19626663 — intervention group
Group type: COMPARATOR
Intervention: INGAP peptide 300 mg/day
Number of subjects: 189
Study 19626663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 17377106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (intraoperative 0.3 mg/kg and postoperative infusion at 0.1 mg x kg(‐1) x h(‐1))
Number of subjects: 120
Study 17377106 — intervention group
Group type: COMPARATOR
Intervention: Control (equivalent volume/rate of normal saline)
Number of subjects: 120
Study 15848980 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Plaque Control 3D (Electric toothbrush)
Number of subjects: 30
Study 15848980 — intervention group
Group type: COMPARATOR
Intervention: SuperBrush (Manual triple-headed brush)
Number of subjects: 30
Study 15848980 — intervention group
Group type: COMPARATOR
Intervention: CrossAction (Manual toothbrush)
Number of subjects: 30
Study 11371693 — intervention group
Group type: EXPERIMENTAL
Intervention: VOICES/VOCES intervention
Number of subjects: 10000
Study 10434906 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA level over 20 ng ml‐1
Number of subjects: 102
Study 10434906 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA level below 20 ng ml‐1 and Gleason score below 6
Number of subjects: 102
Study 10434906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean PSA values of men with skeletal metastases
Number of subjects: 102
Study 10434906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean PSA values of men with locally confined disease
Number of subjects: 102
Study 10434906 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA values of men with lymph node metastasis
Number of subjects: 102
Study 8140873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 30
Study 8140873 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 30
Study 8140873 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline values)
Number of subjects: 30
Study 3555604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 22
Study 29332760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic compression + kinesiotherapy (G1, n = 10)
Number of subjects: 20
Study 29332760 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (G2, n = 10)
Number of subjects: 20
Study 27912108 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication support program
Number of subjects: 110
Study 27912108 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 110
Study 25054304 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive recovery (PAS)
Number of subjects: 11
Study 25054304 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (ACT)
Number of subjects: 11
Study 25054304 — intervention group
Group type: COMPARATOR
Intervention: Cold-water immersion (CWI)
Number of subjects: 11
Study 25054304 — intervention group
Group type: COMPARATOR
Intervention: Ingestion of a recovery drink (NUTR)
Number of subjects: 11
Study 22229527 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (video and brochure)
Number of subjects: 69
Study 22229527 — intervention group
Group type: COMPARATOR
Intervention: Control (teaching session and Q&A)
Number of subjects: 69
Study 21478817 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 58
Study 21478817 — intervention group
Group type: COMPARATOR
Intervention: CNI therapy
Number of subjects: 58
Study 19252046 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram for 20 weeks with care manager monitoring
Number of subjects: 60
Study 19252046 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy for 12 weekly sessions followed by two monthly booster sessions
Number of subjects: 60
Study 16988200 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg 2-hour intravenous infusion
Number of subjects: 32
Study 16988200 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg oral administration twice daily
Number of subjects: 32
Study 16988200 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg/d continuous intravenous infusion
Number of subjects: 32
Study 15163481 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent, intranasal, live attenuated influenza virus vaccine
Number of subjects: 0
Study 15163481 — intervention group
Group type: EXPERIMENTAL
Intervention: Events on days with any symptom during the entire outcome period
Number of subjects: 0
Study 15163481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost benefit analysis based on specific case definition
Number of subjects: 0
Study 15163481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost benefit analysis based on sensitive case definition
Number of subjects: 0
Study 10912948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (200 mg/m2, with possible escalation to 250 mg/m2), administered as a 360 min infusion on days 1, 8, and 15 of a 28-day cycle.
Number of subjects: 18
Study 9487432 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (corticosteroid)
Number of subjects: 30
Study 9487432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar infarction or atrophy on CT
Number of subjects: 30
Study 1396894 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine surfactant (Curosurf) replacement
Number of subjects: 100
Study 1396894 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant treatment)
Number of subjects: 100
Study 2856785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 44
Study 2856785 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 44
Study 2856785 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Captopril
Number of subjects: 44
Study 2856785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg single dose)
Number of subjects: 640
Study 30650326 — intervention group
Group type: COMPARATOR
Intervention: Primaquine (15 mg once daily for 14 days)
Number of subjects: 640
Study 30650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Number of subjects: 640
Study 30650326 — intervention group
Group type: COMPARATOR
Intervention: Primaquine
Number of subjects: 640
Study 30650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine vs. Primaquine
Number of subjects: 640
Study 29879450 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warning label
Number of subjects: 994
Study 29879450 — intervention group
Group type: EXPERIMENTAL
Intervention: Text warning label
Number of subjects: 994
Study 29879450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar information label
Number of subjects: 994
Study 29879450 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating (HSR) label
Number of subjects: 994
Study 29879450 — intervention group
Group type: COMPARATOR
Intervention: Control group (no label)
Number of subjects: 994
Study 27574259 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 150
Study 27574259 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous transfusion (PAT)
Number of subjects: 150
Study 27574259 — intervention group
Group type: COMPARATOR
Intervention: Routine drainage (control)
Number of subjects: 150
Study 24523332 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin (Eprex) administered hypodermically 10,000 units 3 times a week during 6 months
Number of subjects: 14
Study 24523332 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 14
Study 22949632 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive listening devices (classroom FM systems) used for 1 year
Number of subjects: 0
Study 22949632 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (children with dyslexia not using FM system)
Number of subjects: 0
Study 19175372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 585/1,064-nm laser
Number of subjects: 16
Study 19175372 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 16
Study 17134797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor Glove System
Number of subjects: 26
Study 17134797 — intervention group
Group type: COMPARATOR
Intervention: Conventional sensory re‐education
Number of subjects: 26
Study 15218410 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg IA apraclonidine
Number of subjects: 80
Study 15218410 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg IA clonidine
Number of subjects: 80
Study 15218410 — intervention group
Group type: COMPARATOR
Intervention: IA normal saline
Number of subjects: 80
Study 15218410 — intervention group
Group type: COMPARATOR
Intervention: 50 microg IA apraclonidine
Number of subjects: 80
Study 12375395 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS4-ACS6
Number of subjects: 300
Study 12375395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 9821025 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin (UFH)
Number of subjects: 387
Study 9821025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low molecular weight heparin (LMWH)
Number of subjects: 387
Study 9821025 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (LMWH)
Number of subjects: 387
Study 9821025 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 387
Study 8605054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP; 300 mg monthly)
Number of subjects: 197
Study 8605054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX; 160 mg trimethoprim and 800 mg sulfamethoxazole every other day)
Number of subjects: 197
Study 8605054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone-pyrimethamine (DP; 100 mg weekly dapsone and 25 mg biweekly pyrimethamine)
Number of subjects: 197
Study 8605054 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (AP)
Number of subjects: 197
Study 8605054 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (CTX)
Number of subjects: 197
Study 8605054 — intervention group
Group type: COMPARATOR
Intervention: Dapsone-pyrimethamine (DP)
Number of subjects: 197
Study 2529731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.15 microgram/kg)
Number of subjects: 100
Study 2529731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2529731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.75 microgram/kg)
Number of subjects: 100
Study 2529731 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.35 mg/kg)
Number of subjects: 100
Study 2529731 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.04 mg/kg)
Number of subjects: 100